|
Synonyms: BYM-338 | BYM338
Compound class:
Antibody
Comment: Bimagrumab is an investigational monoclonal antibody that binds to activin type II A and B receptors to block activin and myostatin signalling in muscles and adipose tissue. It was originally intended to combat age-related muscle loss and other muscle-wasting conditions. Most recently it has been repositioned as a counter measure for the muscle loss in patients using GLP-1 agonist anti-obesity drugs such as semaglutide and tirzepatide.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Bimagrumab is a clinical candidate that is under clinical investigation. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Bimagrumab primarily targets the type II activin receptor ACVR2B [1], which is a type II receptor serine/threonine kinase. The antibody also has high affinity for ACVR2A, but this is much lower in comparison to ACVR2B binding. This action blocks myostatin-induced SMAD pathway signalling, which is hypothesised to improve the formation of skeletal muscle [2-3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01925209 | Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients | Phase 2/Phase 3 Interventional | Novartis | 4 | |
| NCT02333331 | Dose Range Finding Study of Bimagrumab in Sarcopenia | Phase 2 Interventional | Novartis | 6 | |
| NCT02152761 | Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery | Phase 2 Interventional | Novartis | 5 | |
